| General Information | |
|---|---|
| ZINC ID | ZINC000029126983 |
| Molecular Weight (Da) | 469 |
| SMILES | Cc1c(C(=O)N(C)CCc2ccccc2)oc2ccc(S(=O)(=O)N3C[C@@H](C)C[C@@H](C)C3)cc12 |
| Molecular Formula | C26N2O4S1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.227 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 33 |
| LogP | 4.812 |
| Activity (Ki) in nM | 173.78 |
| Polar Surface Area (PSA) | 79.21 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.00983691 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 15 |
| Fraction csp3 | 0.42 |
| Ilogp | 4.3 |
| Xlogp3 | 5.31 |
| Wlogp | 5.42 |
| Mlogp | 3.02 |
| Silicos-it log p | 3.88 |
| Consensus log p | 4.39 |
| Esol log s | -5.97 |
| Esol solubility (mg/ml) | 0.000508 |
| Esol solubility (mol/l) | 0.00000108 |
| Esol class | Moderately |
| Ali log s | -6.72 |
| Ali solubility (mg/ml) | 0.0000883 |
| Ali solubility (mol/l) | 0.00000018 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.49 |
| Silicos-it solubility (mg/ml) | 0.0000151 |
| Silicos-it solubility (mol/l) | 3.22E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.39 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.54 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.561 |
| Logd | 4.511 |
| Logp | 5.208 |
| F (20%) | 0.007 |
| F (30%) | 0.005 |
| Mdck | - |
| Ppb | 98.11% |
| Vdss | 1.017 |
| Fu | 2.14% |
| Cyp1a2-inh | 0.541 |
| Cyp1a2-sub | 0.913 |
| Cyp2c19-inh | 0.956 |
| Cyp2c19-sub | 0.914 |
| Cl | 6.86 |
| T12 | 0.052 |
| H-ht | 0.996 |
| Dili | 0.991 |
| Roa | 0.515 |
| Fdamdd | 0.869 |
| Skinsen | 0.04 |
| Ec | 0.003 |
| Ei | 0.021 |
| Respiratory | 0.037 |
| Bcf | 1.464 |
| Igc50 | 4.605 |
| Lc50 | 5.556 |
| Lc50dm | 4.205 |
| Nr-ar | 0.005 |
| Nr-ar-lbd | 0.01 |
| Nr-ahr | 0.332 |
| Nr-aromatase | 0.665 |
| Nr-er | 0.164 |
| Nr-er-lbd | 0.005 |
| Nr-ppar-gamma | 0.008 |
| Sr-are | 0.729 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.02 |
| Sr-mmp | 0.716 |
| Sr-p53 | 0.013 |
| Vol | 478.598 |
| Dense | 0.978 |
| Flex | 0.28 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.525 |
| Synth | 3.149 |
| Fsp3 | 0.423 |
| Mce-18 | 85.027 |
| Natural product-likeness | -1.35 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |